Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117939 | 0.87 | SMN1; SMN2 (0.54) | MEN1KMT2ATDP1SMN1; SMN2HPGD | |
| SCHEMBL2117203 | 0.83 | SMN1; SMN2 (0.50) | MEN1KMT2ATDP1SMN1; SMN2HPGD | |
| SCHEMBL2119175 | 0.81 | TDP1 (0.56) | TDP1SMN1; SMN2MAPTTTRALDH1A1 | |
| SCHEMBL2117921 | 0.81 | LMNA (0.59) | MEN1KMT2ATDP1SMN1; SMN2MAPT | |
| SCHEMBL2117510 | 0.79 | TSHR (0.64) | MEN1KMT2ASMN1; SMN2HPGDMAPT | |
| SCHEMBL3438960 | 0.79 | SMN1; SMN2 (0.48) | MEN1KMT2ATDP1SMN1; SMN2HPGD | |
| SCHEMBL16299847 | 0.79 | TSHR (0.53) | MEN1KMT2ATDP1SMN1; SMN2HPGD | |
| SCHEMBL2118932 | 0.78 | MAPT (0.52) | TDP1SMN1; SMN2MAPTTTRALDH1A1 | |
| SCHEMBL29996006 | 0.78 | SMN1; SMN2 (0.65) | MEN1KMT2ATDP1SMN1; SMN2HPGD | |
| SCHEMBL10445559 | 0.78 | SMN1; SMN2 (0.65) | MEN1KMT2ATDP1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399696-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399696-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399696-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8232422-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232422-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232422-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-8053591-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053591-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053591-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | MEN1 1560/4885KMT2A 4645/4885TDP1 1065/4885 |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | MEN1 1560/4885KMT2A 4645/4885TDP1 1065/4885 |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | MEN1 1560/4885KMT2A 4645/4885TDP1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.